wet-amd
(2)
Jason Ehrlich
Jason Ehrlich is the co-founder and CEO of Ollin Biosciences, an Austin-based clinical-stage biopharma launched in September 2025 with $100 million to build best-in-disease eye medicines. An MD-PhD ophthalmologist trained at Princeton and Stanford, he spent a decade at Genentech/Roche helping shepherd retina drugs including Lucentis and the bispecific faricimab (Vabysmo), then served five years as chief medical and development officer at Kodiak Sciences. At Ollin he is taking direct aim at the market leader: in early 2026 his lead asset OLN324 beat faricimab head-to-head in a randomized Phase 1b study, drying retinas faster and deeper with a clean safety record.
Ollin Biosciences
Ollin Biosciences is an Austin-based clinical-stage biopharmaceutical company building a portfolio of best-in-disease therapies for vision-threatening eye diseases. Founded in 2023 and launched publicly in September 2025 with $100M in Series A financing, Ollin in-licenses validated drug candidates and races them through head-to-head trials against the market leaders. Its lead program, OLN324, is a VEGF/Ang2 bispecific antibody for wet age-related macular degeneration and diabetic macular edema that posted superior anatomic results versus Roche's blockbuster Vabysmo in a Phase 1b study.